Switching to dolutegravir-based two-drug regimens (DTG-2DR): performance in clinical practice

被引：0
|
作者：
Hart, J. [1 ]
Katiyar, A. [1 ]
Smith, C. [2 ]
Hunter, A. [1 ]
Burns, F. [1 ]
Youle, M. [1 ]
Barber, T. J. [1 ]
机构：
[1] Royal Free London NHS Fdn Trust, London, England
[2] UCL, London, England
来源：
HIV MEDICINE | 2020年 / 21卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
P18
引用
收藏
页码：21 / 22
页数：2
相关论文
共 31 条
  • [21] Effectiveness and tolerability of the two-drug regimen dolutegravir plus lamivudine in people with HIV-1: a systematic literature review of real-world evidence from clinical practice
    Letang, Emilio
    Priest, Julie
    Di Giambenedetto, Simona
    Monforte, Antonella d'Arminio
    Casado, Jose
    Cabello-Ubeda, Alfonso
    Hocqueloux, Laurent
    Allavena, Clotilde
    Barber, Tristan J.
    Jha, Diwakar
    Kamath, Rahul Dinesh
    Sithamparanathan, Myooran
    van Wyk, Jean
    Evitt, Lee
    HIV MEDICINE, 2022, 23 : 37 - 38
  • [22] Switching from a 3-drug tenofovir alafenamide (TAF)-based regimen (TBR) to a 2-drug dolutegravir/lamivudine (2DR, DTG/3TC FDC) was not associated with a higher frequency of intermittent viremia in suppressed patients in the TANGO study
    Wang, R.
    Horton, J.
    Wright, J.
    Razeek, R.
    Ait-Khaled, M.
    Nascimento, M. C.
    Tenorio, A. R.
    Underwood, M.
    HIV MEDICINE, 2019, 20 : 95 - 95
  • [23] Patient-reported outcomes after switching to a two-drug regimen of dolutegravir plus rilpivirine: Week 100 results from the SWORD-1 and SWORD-2 studies
    Oglesby, A.
    Angelis, K.
    Punekar, Y.
    Lopes, S.
    Antela, A.
    Aboud, M.
    Blair, E.
    Kahl, L.
    Gartland, M.
    Wynne, B.
    Murray, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2018, 21
  • [24] Dolutegravir Plus Lamivudine Two-Drug Regimen: Safety, Efficacy and Diagnostic Considerations for Its Use in Real-Life Clinical Practice-A Refined Approach in the COVID-19 Era
    Cento, Valeria
    Perno, Carlo Federico
    DIAGNOSTICS, 2021, 11 (05)
  • [25] HBcAb Positivity Is a Risk Factor for an Increased Detectability of HIV RNA after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Analysis of a Multicenter Italian Cohort
    Malagnino, Vincenzo
    Teti, Elisabetta
    Compagno, Mirko
    Coppola, Luigi
    Salpini, Romina
    Svicher, Valentina
    Basso, Monica
    Battagin, Giuliana
    Panese, Sandro
    Rossi, Maria Cristina
    Scaggiante, Renzo
    Zago, Daniela
    Iannetta, Marco
    Parisi, Saverio Giuseppe
    Andreoni, Massimo
    Sarmati, Loredana
    MICROORGANISMS, 2021, 9 (02) : 1 - 13
  • [26] Improved metabolic parameters after switching from TAF-based 3-or 4-drug regimen to the 2-drug regimen of DTG/3TC (dolutegravir/lamivudine): The TANGO study
    van Wyk, J.
    Ait-Khaled, M.
    Santos, J.
    Scholten, S.
    Wohlfeiler, M.
    Ajana, F.
    Jones, B.
    Nascimento, M. C.
    Tenorio, A.
    Smith, D.
    Wright, J.
    Wynne, B.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 27 - 27
  • [27] Role of HBcAb Positivity in Increase of HIV-RNA Detectability after Switching to a Two-Drug Regimen Lamivudine-Based (2DR-3TC-Based) Treatment: Months 48 Results of a Multicenter Italian Cohort
    Malagnino, Vincenzo
    Salpini, Romina
    Teti, Elisabetta
    Compagno, Mirko
    Ferrari, Ludovica
    Mulas, Tiziana
    Svicher, Valentina
    Zordan, Marta
    Basso, Monica
    Battagin, Giuliana
    Panese, Sandro
    Rossi, Maria Cristina
    Scaggiante, Renzo
    Zago, Daniela
    Iannetta, Marco
    Parisi, Saverio Giuseppe
    Andreoni, Massimo
    Sarmati, Loredana
    VIRUSES-BASEL, 2023, 15 (01):
  • [28] COMPARISON OF VIRAL REPLICATION FOR THE 2-DRUG REGIMEN (2DR) OF DOLUTEGRAVIR/LAMIVUDINE (DTG/3TC) VERSUS A 3/4-DRUG TENOFOVIR ALAFENAMIDE-BASED REGIMEN (TBR) IN THE TANGO STUDY THROUGH WEEK 96
    Wang, R.
    Wright, J.
    George, N.
    Ait-Khaled, M.
    Lutz, T.
    Osiyemi, O.
    Gorgolas, M.
    Leone, P.
    Wynne, B.
    van Wyk, J.
    Underwood, M.
    Maccarrone, A.
    SEXUAL HEALTH, 2021, 18 (04) : VII - VII
  • [29] Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA)
    Llibre, J. M.
    Alves, C.
    Cheng, C-Y
    Osiyemi, O.
    Galera, C.
    Hocqueloux, L.
    Maggiolo, F.
    Degen, O.
    Blair, E.
    Wynne, B.
    Oyee, J.
    Underwood, M.
    Curtis, L.
    Bontempo, G.
    van Wyk, J.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 13 - 14
  • [30] D Comparison of viral replication for the 2-drug regimen (2DR) of dolutegravir/lamivudine (DTG/3TC) versus a 3/4-drug tenofovir alafenamide-based regimen (TBR) in the TANGO study through week 96
    Wang, R.
    Wright, J.
    George, N.
    Ait-Khaled, M.
    Lutz, T.
    Osiyemi, O.
    Gorgolas, M.
    Leone, P.
    Wynne, B.
    van Wyk, J.
    Underwood, M.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2021, 24 : 21 - 21
1234